Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.81 |
| ▸ | MAPT | P10636 | 4/20 | 0.81 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.81 |
| ▸ | CNR1 | P21554 | 1/20 | 0.81 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.81 |
| ▸ | APAF1 | O14727 | 2/20 | 0.73 |
| ▸ | APEX1 | P27695 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.73 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.73 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.73 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.72 |
| ▸ | MMP2 | P08253 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9483159 | 1.00 | TDP1 (0.81) | TDP1MAPTABCC4CNR1CTDSP1 | |
| SCHEMBL12809649 | 0.92 | TDP1 (0.79) | TDP1MAPTABCC4CNR1CTDSP1 | |
| SCHEMBL9482736 | 0.91 | TDP1 (0.68) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL36995 | 0.89 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL4114437 | 0.89 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL6820723 | 0.89 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL36996 | 0.89 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL16072816 | 0.89 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL3297328 | 0.89 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 | |
| Cefdinir SCHEMBL5919457 | 0.89 | TDP1 (1.00) | TDP1MAPTABCC4CNR1CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394813-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2316469-A1 | Delivery system and methods for protecting and administering dextroamphetamine | Shire LLC (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-2316468-A1 | Delivery system and methods for protecting and administering dextroamphetamine | Shire LLC (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-2266590-A2 | Active agent delivery sytems and methods for protecting and administering active agents | Shire LLC (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090275552-A1 | Therapy for Treating Resistant Bacterial Infections | PATEL MAHESH VITHALBHAI | 2009-11-05 | — | — | US | disclosed |
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | SHIRE LLC (US) | 2009-10-08 | — | — | US | disclosed |
| EP-2015755-A2 | IMPROVEMENTS IN THERAPY FOR TREATING RESISTANT BACTERIAL INFECTIONS | Wockhardt Limited (IN) | 2009-01-21 | — | — | EP | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| EP-1663239-A4 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS SINAI MEDICAL CENTER (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20060142261-A1 | Crystalline anhydrous cefdinir and crystalline cefdinir hydrates | ABBOTT LABORATORIES | 2006-06-29 | — | — | US | disclosed |
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | NU-TEIN CO., LTD. | 2006-06-22 | — | — | US | disclosed |
| US-7060708-B2 | Active agent delivery systems and methods for protecting and administering active agents | NEW RIVER PHARMACEUTICALS INC. (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1663239-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060025399-A1 | Crystalline anhydrous cefdinir and crystalline cefdinir hydrates | ABBOTT LABORATORIES | 2006-02-02 | — | — | US | disclosed |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | CEDARS-SINAI MEDICAL CENTER | 2005-04-28 | — | — | US | disclosed |
| WO-2005025511-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2005-03-24 | — | — | WO | disclosed |
| EP-1490090-A2 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | New River Pharmaceuticals Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040063628-A1 | Active agent delivery systems and methods for protecting and administering active agents | NEW RIVER PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003079972-A2 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | NEW RIVER PARMACEUTICALS INC. (US) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253792-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | TDP1 2667/4885MAPT 2824/4885ABCC4 1144/4885 |
| US-20060134226-A1 | Compositions useful to treat ocular neovascular diseases and macular degeneration | CFD, VEGFA, CFH | TDP1 3879/4885MAPT 1080/4885ABCC4 801/4885 |
| US-20090306228-A1 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS | HDGF, CTSA, IAPP | TDP1 2667/4885MAPT 2824/4885ABCC4 1144/4885 |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | KCNN2, KCNN1, KCNN3 | TDP1 3850/4885MAPT 767/4885ABCC4 172/4885 |
| US-20040063628-A1 | Active agent delivery systems and methods for protecting and administering active agents | HDGF, CTSA, IAPP | TDP1 2667/4885MAPT 2824/4885ABCC4 1144/4885 |
| US-20090275552-A1 | Therapy for Treating Resistant Bacterial Infections | BPGM, MGAM, IL1B | TDP1 4528/4885MAPT 3048/4885ABCC4 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.